Trials / Completed
CompletedNCT06643390
A Study of MK-2225 in Healthy Participants (MK-2225-003)
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2225 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-2225 | Subcutaneous administration |
| OTHER | Placebo | Subcutaneous administration |
Timeline
- Start date
- 2023-11-21
- Primary completion
- 2025-07-14
- Completion
- 2025-07-14
- First posted
- 2024-10-16
- Last updated
- 2025-07-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06643390. Inclusion in this directory is not an endorsement.